Skip to main content

Table 2 Characteristics of patients who did or did not discontinue their ART regimen within the first 12 months

From: Trends and factors associated with modification or discontinuation of the initial antiretroviral regimen during the first year of treatment in the Turkish HIV-TR Cohort, 2011–2017

Characteristic

Total = 3019

Discontinued = 351

Continued = 2668

P

N (%)

N (%)

N (%)

Gender

.083

 Male

2605 (86.3)

292 (83.2)

2313 (86.7)

 

 Female

414 (13.7)

59 (16.8)

355 (13.3)

 

Age (years)

.021

 ≤ 45

2240 (75.0)

244 (69.9)

1996 (75.7)

 

 > 45

746 (25.0)

105 (30.1)

641 (24.3)

 

Mode of transmission

.598

 MSM/Bisexual

1038 (34.4)

115 (32.8)

923 (34.6)

 

 Heterosexual

1683 (55.7)

198 (56.4)

1485 (55.7)

 

 IDU

6 (0.2)

1 (0.3)

5 (0.2)

 

 Other

62 (2.1)

11 (3.1)

51 (1.9)

 

 Unknown

230 (7.6)

26 (7.4)

204 (7.6)

 

Pretreatment CD4 cell count (cells/mm3)

.011

 < 200

723 (25.6)

104 (31.4)

619 (24.8)

 

 ≥ 200

2103 (74.4)

227 (68.6)

1876 (75.2)

 

Pretreatment viral load (copies/mL)

.213

 < 100,000

1262 (45.0)

135 (41.7)

1127 (45.4)

 

 ≥ 100,000

1545 (55.0)

189 (58.3)

1356 (54.6)

 

AIDS diagnosis

.006

 Yes

793 (26.3)

114 (32.5)

679 (25.4)

 

 No

2226 (73.7)

237 (67.5)

1989 (74.6)

 

ART regimen type

<.001

 InSTI

1135 (37.6)

63 (17.9)

1072 (40.2)

 

 InSTI/PI

6 (0.2)

1 (0.3)

5 (0.2)

 

 NNRTI

798 (26.4)

109 (31.1)

689 (25.8)

 

 PI

1080 (35.8)

178 (50.7)

902 (33.8)

 

Type of initial ART

<.001

 EFV/TDF/FTC

750 (24.8)

101 (28.8)

649 (24.3)

 

 LPV/r/TDF/FTC

743 (24.6)

121 (34.5)

622 (23.3)

 

 EVG/c/TDF/FTC

680 (22.5)

39 (11.1)

641 (24.0)

 

 DTG/TDF/FTC

351 (11.6)

10 (2.8)

341 (12.8)

 

 DRV/r/TDF/FTC

276 (9.1)

34 (9.7)

242 (9.1)

 

 RAL/TDF/FTC

65 (2.2)

12 (3.4)

53 (2.0)

 

 LPV/r/ZDV/3TC

53 (1.8)

21 (6.0)

32 (1.2)

 

 EFV/ZDV/3TC

39 (1.3)

7 (2.0)

32 (1.2)

 

 Other

62 (2.1)

6 (1.7)

56 (2.1)

 

Year of ART initiation

.031

 2011–2014

1495 (49.5)

193 (55.0)

1302 (48.8)

 

 2015–2017 Feb

1524 (50.5)

158 (45.0)

1366 (51.2)

 
  1. Missing values: 6% for CD4 cell counts, 7% for pretreatment viral load
  2. 3TC lamivudine, DRV darunavir, DTG dolutegravir, EFV efavirenz, EVG/c elvitegravir/cobicistat, FTC emtricitabine, InSTI integrase strand transfer inhibitor, IDU injection drug user, LPV lopinavir, MSM men who have sex with men, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, RAL raltegravir, r ritonavir, TDF tenofovir disoproxil fumarate, ZDV zidovudine
Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us